MRS2 and pachyonychia congenita: Six candidate proteins were verified using ELISA (alpha-1-antichymotrypsin (AACT), alpha-1-antitrypsin (A1AT), leucine-rich alpha-2-glycoprotein (LRG), thrombospondin-1 (THBS1) and haptoglobin (HPT)) or AAL lectin-ELISA (HPT and lumican (LUM)) in serum samples from 34 PC patients and 142 non-PC controls, which yielded a three-marker panel (AACT, THBS1 and HPT) with higher diagnostic potency for PC than the single biomarker CA19-9 [13].